|
|
Blood, 15 January 2004, Vol. 103, No. 2, pp. 607-612.
Prepublished online as a Blood First Edition Paper on September 25, 2003; DOI 10.1182/blood-2003-08-2861.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13
Koichi Kokame,
Masanori Matsumoto,
Yoshihiro Fujimura, and
Toshiyuki Miyata
From the National Cardiovascular Center Research Institute, Suita, Osaka, Japan; and the Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Nara, Japan.
ADAMTS-13 was recently identified as a new hemostatic factor, von Willebrand factor (VWF)–cleaving protease. Either congenital or acquired defects of the enzymatic activity lead to thrombotic thrombocytopenic purpura (TTP). ADAMTS-13 specifically cleaves a peptidyl bond between Y1605 and M1606 in the A2 domain of VWF. Here, we determined the minimal region recognized as a specific substrate by ADAMTS-13. A series of partial deletions in the A2 domain flanked with N- and C-terminal tags were expressed in Escherichia coli and affinity-purified. These purified proteins were incubated with human plasma, subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), and analyzed by Western blot. Judging from mobility shifts, all constructs except one were cleaved at the expected site. Data suggested that a minimal region as a functional substrate consisted of 73 amino acid residues from D1596 to R1668 of VWF, designated VWF73, and that further deletion of the E1660-R1668 region led to the loss of cleavage by ADAMTS-13. VWF73 was not cleaved by plasma from patients with congenital or acquired TTP, but cleaved by plasma from patients with hemolytic uremic syndrome, suggesting that VWF73 is a specific substrate forADAMTS-13. Thus, VWF73 will be a useful seed to develop a new rapid assay to determine ADAMTS-13 activity.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
F. Banno, A. K. Chauhan, K. Kokame, J. Yang, S. Miyata, D. D. Wagner, and T. Miyata
The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation
Blood,
May 21, 2009;
113(21):
5323 - 5329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Laje, D. Shang, W. Cao, M. Niiya, M. Endo, A. Radu, N. DeRogatis, F. Scheiflinger, P. W. Zoltick, A. W. Flake, et al.
Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy
Blood,
March 5, 2009;
113(10):
2172 - 2180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-C. Chung, T. G. Popova, S. C. Jorgensen, L. Dong, V. Chandhoke, C. L. Bailey, and S. G. Popov
Degradation of Circulating von Willebrand Factor and Its Regulator ADAMTS13 Implicates Secreted Bacillus anthracis Metalloproteases in Anthrax Consumptive Coagulopathy
J. Biol. Chem.,
April 11, 2008;
283(15):
9531 - 9542.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. T. Serrano, J. Kim, D. Wang, B. Dragulev, J. D. Shannon, H. H. Mann, G. Veit, R. Wagener, M. Koch, and J. W. Fox
The Cysteine-rich Domain of Snake Venom Metalloproteinases Is a Ligand for von Willebrand Factor A Domains: ROLE IN SUBSTRATE TARGETING*
J. Biol. Chem.,
December 29, 2006;
281(52):
39746 - 39756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Gao, P. J. Anderson, E. M. Majerus, E. A. Tuley, and J. E. Sadler
Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease
PNAS,
December 12, 2006;
103(50):
19099 - 19104.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-J. Wu, K. Fujikawa, B. A. McMullen, and D. W. Chung
Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor
PNAS,
December 5, 2006;
103(49):
18470 - 18474.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Banno, K. Kokame, T. Okuda, S. Honda, S. Miyata, H. Kato, Y. Tomiyama, and T. Miyata
Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura
Blood,
April 15, 2006;
107(8):
3161 - 3166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Zanardelli, J. T. B. Crawley, C. K. N. C. K. Chion, J. K. Lam, R. J. S. Preston, and D. A. Lane
ADAMTS13 Substrate Recognition of von Willebrand Factor A2 Domain
J. Biol. Chem.,
January 20, 2006;
281(3):
1555 - 1563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Anderson, K. Kokame, and J. E. Sadler
Zinc and Calcium Ions Cooperatively Modulate ADAMTS13 Activity
J. Biol. Chem.,
January 13, 2006;
281(2):
850 - 857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Soejima, H. Nakamura, M. Hirashima, W. Morikawa, C. Nozaki, and T. Nakagaki
Analysis on the Molecular Species and Concentration of Circulating ADAMTS13 in Blood
J. Biochem.,
January 1, 2006;
139(1):
147 - 154.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Nishio, P. J. Anderson, X. L. Zheng, and J. E. Sadler
Binding of platelet glycoprotein Ib{alpha} to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13
PNAS,
July 20, 2004;
101(29):
10578 - 10583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Banno, K. Kaminaka, K. Soejima, K. Kokame, and T. Miyata
Identification of Strain-specific Variants of Mouse Adamts13 Gene Encoding von Willebrand Factor-cleaving Protease
J. Biol. Chem.,
July 16, 2004;
279(29):
30896 - 30903.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Sadler, J. L. Moake, T. Miyata, and J. N. George
Recent Advances in Thrombotic Thrombocytopenic Purpura
Hematology,
January 1, 2004;
2004(1):
407 - 423.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
